ValueQ3, 24Q4, 24TTMSelling/general/admin expenses123.66 M123.02 M518.73 MResearch & development199.16 M213.25 M825 MOperating income236.54 M235.22 M872.19 MNon-Operating Income, Total49 K-146 K198 KInterest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses000Unusual income/expense49 K-146 K198 KPretax income236.59 M235.07 M872.39 MEquity in earnings———Taxes58.84 M8.16 M158.64 MNon-controlling/minority interest———After tax other income/expense-1.36 M2.35 M11.61 MNet income before discontinued operations193.58 M244.53 M782.57 MDiscontinued operations———Net income193.58 M244.53 M782.57 MDilution adjustment———Preferred dividends———Diluted net income available to common stockholders193.58 M244.53 M782.57 MBasic earnings per share (Basic EPS)0.720.912.88Diluted earnings per share (Diluted EPS)0.690.892.78Average basic shares outstanding268.42 M271.57 M1.09 BDiluted shares outstanding278.54 M281.86 M1.13 BEBITDA243.96 M222.36 M881.44 MEBIT236.54 M215.41 M852.38 MCost of revenue18.57 M26.48 M83.7 MOther cost of goods sold———Depreciation & amortization (cash flow)7.42 M6.95 M29.05 M
Exelixis Inc
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.